3Reginster JY, Felsenberg D, Boonen S,et al. Effects of long term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year,randomized,placebo-controlled trail[J]. Arthritis Rheum,2008,58(6) : 1687-1695.
4Ing-Lorenzini K,Desmeules J,Plachta O,et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates [J]. Drug Safety, 2009,32(9) : 775-785.
5Peng S,Zhang G,Zhang BT,et al. The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats [J]. Bone, 2013,55 ( 1 ) : 230-240.
6Rodriguez M,Urena-Torres P,P6tavy F,et al. Calcium- mediated parathyroid hormone suppression to assess pro- gression of secondary hyperparathyroidism during treat- merit among incident dialysis patients [J]. The Journal of Clinical Endocrinology & Metabolism, 2013,98 (2) : 618 - 625.
7Paul EG,Shangle Q,Angela M,et al. Effects of the steroidal aromatase inhibitor exemestane and the monsteroidal aro- matase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats[J]. Clinical Cancer Research ,2004, 10(17) : 5717-5723.
8Mosekilde L,Vestergaard P,Rejnmark L The pathogenesis, treatment and prevention of osteoporosis in men [J]. Drugs ,2013,73 (1) : 15-29.
9Wu XY,Yu SJ,Zhang H,et al. Early bone mineral density decrease is associated with FSH and LH, not estrogen[J]. Clinica Chimiea Acta,2013,415(4) :69-73.
